Teslake
Solving the biggest problems in spinal deformity surgeries
Overview
Raised: $41,672
Rolling Commitments ($USD)
05/04/2024
$171
15
2019
Healthcare & Pharmaceuticals
Biotech
B2B2C
High
High
Summary Profit and Loss Statement
FY 2022 | FY 2021 | |
---|---|---|
Revenue |
$868,427 |
$368,602 |
COGS |
$41,253 |
$23,706 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-182,618 |
$-264,514 |
Summary Balance Sheet
FY 2022 | FY 2021 | |
---|---|---|
Cash |
$82,470 |
$662,833 |
Accounts Receivable |
$100,100 |
$40,049 |
Total Assets |
$1,617,249 |
$1,626,876 |
Short-Term Debt |
$443,021 |
$268,855 |
Long-Term Debt |
$2,777,387 |
$2,776,071 |
Total Liabilities |
$3,220,408 |
$3,044,926 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual